Highlights

  • Silexion dosed the first patient in its Phase 2/3 SIL204 study for locally advanced pancreatic cancer.
  • The company is developing SIL204 as an RNA interference treatment targeting KRAS-driven cancers.
  • Preclinical work released in September examined how SIL204 may reach systemic circulation through endogenous uptake mechanisms.
  • Silexion announced a one-for-24 reverse share split effective in November as the clinical program continued.

The first patient receiving SIL204 marks a shift from trial preparation to active clinical dosing for Silexion Therapeutics (NASDAQ:SLXN). Its pancreatic cancer program is now undergoing Phase 2/3 evaluation, giving the company a defined clinical path alongside recently reported laboratory findings and a November share-capital adjustment.

First Patient Dosed in Pancreatic Cancer Study

On September 30, 2026, Silexion announced successful dosing of the first patient in its Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer. The event followed the company’s earlier initiation of the study and regulatory clearance work in Israel and Germany. First dosing is an operational milestone that confirms the study moved into patient treatment; it does not provide a clinical efficacy result. Subsequent progress will depend on patient enrollment, protocol execution and analysis of the specified study endpoints.

A KRAS-Targeted Development Approach

SIL204 is a second-generation small interfering RNA therapy candidate designed for cancers driven by KRAS mutations. The company has positioned locally advanced pancreatic cancer as its lead clinical indication. The treatment’s RNA interference design seeks to intervene in molecular signalling associated with KRAS-driven disease. Clinical studies are necessary to determine whether this biological approach produces meaningful benefits in patients. Silexion’s disclosed trial status should therefore be separated from the potential efficacy the program is intended to investigate.

Preclinical Research Adds Mechanistic Detail

On September 28, Silexion released preclinical findings exploring endogenous systemic uptake of SIL204. The company also reported preclinical immune-sensitization observations earlier in August. These studies examine how its candidate behaves in laboratory and experimental settings and help inform development planning. They are not substitutes for randomized clinical outcomes. Their importance lies in clarifying potential mechanisms and shaping the next stages of testing rather than demonstrating an approved treatment.

Capital Adjustment and Clinical Priorities

Silexion announced a one-for-24 reverse share split on November 9, 2026. That action changes the number of shares outstanding and the per-share trading presentation, but does not itself alter the clinical stage of SIL204. The principal program remains the ongoing Phase 2/3 investigation. The next meaningful operational updates will relate to trial execution, patient progress and future reported findings. A development-stage therapy remains subject to clinical and regulatory evaluation before any commercialization decision.

Silexion Therapeutics shares traded at USD 3.23 on November 11, 2026, advancing 23.58% during the session.